<DOC>
	<DOCNO>NCT01888042</DOCNO>
	<brief_summary>It open label , multicentric , phase II study assess efficacy everolimus ( give per o ) first line treatment kidney cancer bad prognosis . 92 patient include ( anticipate ) . The treatment everolimus continue progression , significant toxicity withdraw consent</brief_summary>
	<brief_title>Assessing Everolimus Fist Line Treatment Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Metastatic kidney cancer , regardless histology ( except Bellini carcinoma ) , measurable evaluable disease 2 . Age &gt; = 18 year 3 . With Karnofsky ≥ 60 4 . Without prior treatment metastatic cancer ( chemotherapy , target therapy , mTOR inhibitor ) 5 . Bad prognosis , define follow : least three follow six criterion poor prognosis : Karnofsky &lt; 80 LDH &gt; 1.5 ULN hemoglobin &lt; LLN correct calcium &gt; 2.5 mmol / l ( 10 mg / dl ) Time frame initial diagnostic treatment &lt; 1 year More one metastatic site 6. medullary function : neutrophil ≥ 1.5 x 109 / L , Platelets ≥ 100 x 109 / L , Hb &gt; 8g/dL 7 . Hepatic function : bilirubin : ≤ 1.5 x ULN , ALT AST ≤ 2.5x ULN absence hepatic metastasis ≤ 5x ULN hepatic metastasis document 8 . Renal function : creatinine &lt; 1.5 x ULN 9 . Life expectancy &gt; 3 month , 10 . Patient sign informed consent agree comply requirement trial 1 . Previous treatment chemotherapy , target therapy , mTOR inhibitor 2 . Previous radiotherapy last 2 week 3 . Chronic treatment corticoid immunosuppressive agent except substitutive opotherapy.. A washout period least 8 day must respect patient inclusion . 4 . Patients brain metastasis untreated uncontrolled prior treatment . The nonprogression metastases must prove compare two brain scan separate minimum interval 6 week . 5 . Active bleed 6 . Patient positive serology HBs ( Ag HBs ( + ) AC antiHBc ( + ) 7 . Hypersensitivity everolimus , sirolimus , rapamycin derivative excipients 8 . Severe uncontrolled medical pathology : unstable angina , symptomatic heart failure , myocardial infarction ≤ 6 month randomization , severe rhythm disorder , Uncontrolled diabetes glycaemia &gt; 1.5X ULN . Active uncontrolled infection . cirrhosis chronic active hepatitis , severe alteration lung function ( &gt; 50 % decrease FEV vital capacity ) 9 . Other cancer within past 3 year , exception basal cell carcinoma carcinoma situ cervix 10 . Pregnant lactate woman , adult refuse effective contraceptive method 11 . Participation another clinical trial investigational drug 12 . Refusal patient comply rule clinical trial 13 . Person deprive liberty person guardianship , inability submit medical treatment test geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>